# Pfizer: Phase 2 study terminated, 42 enrolled (Pulmonary Hypertension)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 |
| NCT ID | NCT07073820 |
| Phase | Phase 2 |
| Status | terminated |
| Conditions | Pulmonary Hypertension |
| Intervention types | drug |
| Target enrollment | 42 |
| Site countries | United States, Australia, Belgium, China, Czechia, Germany, Japan, South Korea, Spain, United Kingdom |
| Posted | 2025-07-18 |
| Planned start | 2025-11-10 |
| Event | Terminated |
| Event date | 2026-10-09 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07073820). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.